Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023

January 16, 2026

Abstract

Drug use disorders (DUDs) are emerging global public health challenges. Here we investigated the global and regional estimates of the prevalence and burden of DUDs, including amphetamine, cannabis, cocaine and opioid use disorders, from 1990 to 2023 for 204 countries and territories by using the Global Burden of Disease Study 2023. Overall, trends in global age-standardized disability-adjusted life-years of DUDs increased from 169.3 (95% uncertainty interval (95% UI), 134.4–203.9) per 100,000 people in 1990 to 212.0 (95% UI, 179.2–245.6) in 2023. In 2023, both prevalence and burden of DUDs were higher in high-income countries, particularly in the USA. The most prevalent DUDs in 2023 were cannabis use disorder (age-standardized prevalence, 270.8 (95% UI, 201.7–350.0) per 100,000 people) and opioid use disorder (205.9 (95% UI, 178.7–235.0)). Particularly, opioid use disorder showed a nearly twofold increase in prevalence and burden between 1990 and 2023. In 2023, compared with countries where cannabis use was illegal, countries permitting both recreational and medical cannabis use had higher prevalence rates for all types of DUDs. Proactive and effective policies are essential to mitigate the increasing global burden of DUDs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: World map of age-standardized prevalence and DALYs per 100,000 population attributable to DUDs for both sexes across 204 countries in 2023.
Fig. 2: Global trends in prevalence and DALYs (numbers and age-standardized rate per 100,000 population) between 1990 and 2023, with 95% UI for the comparison of DUDs by substance type.
Fig. 3: Distribution of DALYs numbers and rates per 100,000 population for 2023, with 95% UI for DUDs by age group and sex.
Fig. 4: Age-standardized DALYs per 100,000 population for DUDs attributed to each drug disorder in 2023, adjusted for the legalization level of cannabis use across 204 countries.
Fig. 5: Age-standardized prevalence and DALYs per 100,000 population by DUDs and cannabis legalization level across 204 countries in 2023.
Fig. 6: Age-standardized percentage change in prevalence of DUDs by SDI, before and during pandemic periods (2015–2019 and 2019–2023).

Data availability

The findings from this study were produced using data available in public online repositories or in the published literature, data that are publicly available on request from the data provider and data that are not publicly available due to restrictions by the data provider and which were used under license for the current study. Details on data sources can be found on the GHDx website, including information about the data provider and links to where the data can be accessed or requested (where available). To download the data used in these analyses, please visit the Global Health Data Exchange GBD 2023 website (accessed on 18 September 2025) at https://ghdx.healthdata.org/gbd-2023/sources.

Code availability

Our study follows the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER; Supplementary Table 16). All code used for the GBD 2023 analyses is publicly available online at https://ghdx.healthdata.org/gbd-2023/code.

References

  1. GBD 2016 Alcohol and Drug Use Collaborators. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry 5, 987–1012 (2018).

    Article 

    Google Scholar
     

  2. Castaldelli-Maia, J. M. et al. Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019. Lancet Psychiatry 10, 85–97 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  3. Stone, J. et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect. Dis. 18, 1397–1409 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  4. Gomes, T. et al. Trends in opioid toxicity-related deaths in the US before and after the start of the COVID-19 pandemic, 2011–2021. JAMA Netw. Open 6, e2322303 (2023).

    Article 
    PubMed Central 

    Google Scholar
     

  5. Zhang, T. et al. Burden of drug use disorders in the United States from 1990 to 2021 and its projection until 2035: results from the GBD study. BMC Public Health 24, 1639 (2024).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  6. Ciccarone, D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr. Opin. Psychiatry 34, 344–350 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  7. Mars, S. G., Rosenblum, D. & Ciccarone, D. Illicit fentanyls in the opioid street market: desired or imposed?. Addiction 114, 774–780 (2019).

    Article 
    PubMed 

    Google Scholar
     

  8. Yang, L. H., Wong, L. Y., Grivel, M. M. & Hasin, D. S. Stigma and substance use disorders: an international phenomenon. Curr. Opin. Psychiatry 30, 378–388 (2017).

    Article 
    PubMed 

    Google Scholar
     

  9. Shen, J. et al. Prevalence, incidence, deaths, and disability-adjusted life-years of drug use disorders for 204 countries and territories during the past 30 years. Asian J. Psychiatr. 86, 103677 (2023).

    Article 
    PubMed 

    Google Scholar
     

  10. The Lancet Regional Health – Americas. Opioid crisis: addiction, overprescription, and insufficient primary prevention. Lancet Reg. Health Am. 23, 100557 (2023).

    PubMed Central 

    Google Scholar
     

  11. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 23, 344–381 (2024).

    Article 

    Google Scholar
     

  12. Hay, S. I. et al. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1873–1922 (2025).

    Article 

    Google Scholar
     

  13. Hammarlund, R., Crapanzano, K. A., Luce, L., Mulligan, L. & Ward, K. M. Review of the effects of self-stigma and perceived social stigma on the treatment-seeking decisions of individuals with drug- and alcohol-use disorders. Subst. Abus. Rehabil. 9, 115–136 (2018).

    Article 
    CAS 

    Google Scholar
     

  14. Post, L. A. et al. Geographic trends in opioid overdoses in the US from 1999 to 2020. JAMA Netw. Open 5, e2223631 (2022).

    Article 
    PubMed 

    Google Scholar
     

  15. Pardo, B. et al. The Future of Fentanyl and Other Synthetic Opioids (Rand Corporation, 2019).

  16. Al-Tayyib, A., Koester, S., Langegger, S. & Raville, L. Heroin and methamphetamine injection: an emerging drug use pattern. Subst. Use Misuse 52, 1051–1058 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  17. Jones, C. M., Einstein, E. B. & Compton, W. M. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010–2016. JAMA 319, 1819–1821 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  18. Palamar, J. J., Le, A., Carr, T. H. & Cottler, L. B. Shifts in drug seizures in the United States during the COVID-19 pandemic. Drug Alcohol Depend. 221, 108580 (2021).

    Article 
    PubMed 
    PubMed Central 
    CAS 

    Google Scholar
     

  19. Palamar, J. J., Fitzgerald, N., Carr, T. H., Cottler, L. B. & Ciccarone, D. National and regional trends in fentanyl seizures in the United States, 2017–2023. Int. J. Drug Policy 138, 104417 (2024).

    Article 
    PubMed 

    Google Scholar
     

  20. Strickland, J. C., Havens, J. R. & Stoops, W. W. A nationally representative analysis of “twin epidemics�: rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 204, 107592 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  21. Murray, R. M. & Hall, W. Will legalization and commercialization of cannabis use increase the incidence and prevalence of psychosis?. JAMA Psychiatry 77, 777–778 (2020).

    Article 
    PubMed 

    Google Scholar
     

  22. Kandel, D. & Kandel, E. The gateway hypothesis of substance abuse: developmental, biological and societal perspectives. Acta Paediatr. 104, 130–137 (2015).

    Article 

    Google Scholar
     

  23. Williams, A. R. Cannabis as a gateway drug for opioid use disorder. J. Law Med. Ethics 48, 268–274 (2020).

    Article 
    PubMed 

    Google Scholar
     

  24. Garcia-Perez, A., Aonso-Diego, G., Weidberg, S. & Secades-Villa, R. Testing the cannabis gateway hypothesis in a national sample of Spanish adolescents. Addict. Behav. 144, 107751 (2023).

    Article 
    PubMed 

    Google Scholar
     

  25. M. Filho, A. et al. The carcinogenicity of opium consumption: a systematic review and meta-analysis. Eur. J. Epidemiol. 38, 373–389 (2023).

    Article 
    PubMed Central 

    Google Scholar
     

  26. Volkow, N. D., Jones, E. B., Einstein, E. B. & Wargo, E. M. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry 76, 208–216 (2019).

    Article 
    PubMed 

    Google Scholar
     

  27. Azagba, S., Shan, L., Qeadan, F. & Wolfson, M. Unemployment rate, opioids misuse and other substance abuse: quasi-experimental evidence from treatment admissions data. BMC Psychiatry 21, 22 (2021).

    Article 
    PubMed Central 
    CAS 

    Google Scholar
     

  28. Kravitz-Wirtz, N. et al. Association of Medicaid expansion with opioid overdose mortality in the United States. JAMA Netw. Open 3, e1919066 (2020).

    Article 
    PubMed 

    Google Scholar
     

  29. Ghertner, R. & Groves, L. The opioid crisis and economic opportunity: geographic and economic trends. ASPE Res. Brief. 11, 1–22 (2018).


    Google Scholar
     

  30. Kim, S. et al. Global, regional, and national trends in drug use disorder mortality rates across 73 countries from 1990 to 2021, with projections up to 2040: a global time-series analysis and modelling study. EClinicalMedicine 79, 102985 (2025).

    Article 
    PubMed 

    Google Scholar
     

  31. McKee, S. A. & McRae-Clark, A. L. Correction to: Consideration of sex and gender differences in addiction medication response. Biol. Sex Differ. 13, 38 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  32. Cheong, C. et al. National trends in counseling for stress and depression and COVID-19 pandemic-related factors among adults, 2009–2022: a nationwide study in South Korea: stress, depression, and pandemic. Psychiatry Res. 337, 115919 (2024).

    Article 
    PubMed 

    Google Scholar
     

  33. Bao, Y. et al. Medical marijuana legalization and opioid- and pain-related outcomes among patients newly diagnosed with cancer receiving anticancer treatment. JAMA Oncol. 9, 206–214 (2023).

    Article 
    PubMed 

    Google Scholar
     

  34. Ray, L. A. et al. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Netw. Open 3, e208279 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  35. Wakeman, S. E. et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw. Open 3, e1920622 (2020).

    Article 
    PubMed Central 

    Google Scholar
     

  36. Chambers, L. C. et al. Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. JAMA Netw. Open 6, e2334540 (2023).

    Article 
    PubMed 

    Google Scholar
     

  37. Irvine, M. A. et al. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health 7, e210–e218 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  38. Roberts, H. H., Stone, M. & Isac, A. J. Syringe services programs to reduce intravenous disease transmission in substance use disorders. Nurs. Clin. North Am. 58, 243–256 (2023).

    Article 
    PubMed 

    Google Scholar
     

  39. Fujita-Imazu, S. et al. Evolving trends in drug overdose mortality in the USA from 2000 to 2020: an age-period-cohort analysis. EClinicalMedicine 61, 102079 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  40. Degenhardt, L., Day, C., Gilmour, S. & Hall, W. The “lessons� of the Australian “heroin shortage�. Subst. Abuse Treat. Prev. Policy 1, 11 (2006).

    Article 
    PubMed Central 

    Google Scholar
     

  41. Force, L. M. et al. The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1565–1586 (2025).

    Article 

    Google Scholar
     

  42. Schumacher, A. E. et al. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1731–1810 (2025).

    Article 

    Google Scholar
     

  43. Naghavi, M. et al. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1811–1872 (2025).

    Article 

    Google Scholar
     

  44. Cooper, J. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM–IV–TR). Br. J. Psychiatry 179, 85 (2001).

    Article 

    Google Scholar
     

  45. Johnson, S. C. et al. Public health utility of cause of death data: applying empirical algorithms to improve data quality. BMC Med. Inf. Decis. Mak. 21, 175 (2021).

    Article 

    Google Scholar
     

  46. Chrzanowska, A. et al. Unintentional and intentional drug poisoning deaths, Australia, 2012–2016: drug pattern profile and demographic characteristics. Drug Alcohol Depend. 229, 109112 (2021).

    Article 
    PubMed 

    Google Scholar
     

  47. Rafferty, Q. et al. Global, regional, and national prevalence of kidney failure with replacement therapy and associated aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Glob. Health 13, e1378–e1395 (2025).

    Article 

    Google Scholar
     

  48. Shand, F. L., Slade, T., Degenhardt, L., Baillie, A. & Nelson, E. C. Opioid dependence latent structure: two classes with differing severity? Addiction 106, 590–598 (2011).

    Article 
    PubMed 

    Google Scholar
     

  49. Zhang, T. et al. Age, gender and geographic differences in global health burden of cirrhosis and liver cancer due to nonalcoholic steatohepatitis. J. Cancer 12, 2855–2865 (2021).

    Article 
    PubMed 
    PubMed Central 
    CAS 

    Google Scholar
     

  50. Shingala, M. C. & Rajyaguru, A. Comparison of post hoc tests for unequal variance. Int. J. N. Technol. Sci. Eng. 2, 22–33 (2015).


    Google Scholar
     

  51. Qi, J. et al. National and subnational trends in cancer burden in China, 2005–20: an analysis of national mortality surveillance data. Lancet Public Health 8, e943–e955 (2023).

    Article 
    PubMed 

    Google Scholar
     

  52. Das Gupta, P. Standardization and decomposition of rates from cross-classified data. Genus 50, 171–196 (1994).

    PubMed 

    Google Scholar
     

  53. Chevan, A. & Sutherland, M. Revisiting Das Gupta: refinement and extension of standardization and decomposition. Demography 46, 429–449 (2009).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

Download references

Acknowledgements

This study was funded by the Gates Foundation, the Australian National Health and Medical Research Council and the Queensland Department of Health, Australia. This paper was developed as part of the GBD Collaborator Network and GBD Protocol with support from the GBD Secretariat, IHME and the GBD Collaborator Network under the IHME ID: 4251 (GBD 2023 Substance Use Collaborators). This work was supported by the Yonsei Fellowship, funded by Lee Youn Jae (to J.I.S.). This research was supported by the Ministry of Science and ICT (grant nos. RS-2024-00509257 and IITP-2024-RS-2024-00438239 to D.K.Y.) and the Ministry of Health & Welfare (grant no. RS-2025-02220492 to D.K.Y.), South Korea. The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. All authors had full access to the study data and had final responsibility for the decision to submit for publication.

Author information

Author notes

Authors and Affiliations

Authors

Consortia

Contributions

J.K., H.J.K., M.S.K., J.I.S. and D.K.Y. conceptualized and designed the study. J.K., H.J.K., M.S.K., J.I.S. and D.K.Y. were responsible for the methodology. J.K., H.J.K., M.S.K., J.I.S. and D.K.Y. were responsible for data acquisition. J.K., H.J.K., M.S.K., J.I.S. and D.K.Y. performed statistical analysis and data curation. J.K., H.J.K., M.S.K., J.I.S. and D.K.Y. performed the validation. J.K., H.J.K., M.S.K., J.I.S. and D.K.Y. were responsible for data interpretation. J.K., H.J.K., M.S.K., J.I.S. and D.K.Y. performed the visualization. J.K., H.J.K., M.S.K., J.I.S. and D.K.Y. were responsible for managing the estimation or publications process. J.K., H.J.K. and M.S.K. wrote the original draft of the paper. All authors provided critical revision to the paper. J.I.S. and D.K.Y. supervised the study. J.I.S. and D.K.Y. were responsible for project administration. J.I.S. and D.K.Y. were responsible for funding acquisition. Contributions by the GBD 2023 Global Substance Use Collaborators are described in Supplementary Information.

Corresponding authors

Correspondence to
Jae Il Shin or Dong Keon Yon.

Ethics declarations

Competing interests

S. Afzal reports support for the present manuscript from the Institute of Public Health Lahore; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Dean Institute of Public Health Lahore; support for attending meetings and travel from the Dean Institute of Public Health Lahore; participation on a data safety monitoring board or advisory board with Pakistan National Bioethics Committee, Institution Review Board of Fatima Jinnah Medical University, Ethical Review Board and Data Monitoring Board with the Institute of Public Health Lahore Pakistan, and is in charge of the Clinical Research Organization King Edward Medical University; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with Pakistan Higher Education Commission Research Committee, Pakistan Medical and Dental Research Commission Research and Journals Committee, Pakistan Society of Internal medicine, Pakistan Association of Medical Editors, Medical Microbiology and Infectious Diseases Society, Fellow of Leads International, Fellow of Faculty of Public Heath UK and Fellow of College of Physicians and Surgeons Pakistan; receipt of equipment, materials, drugs, medical writing, gifts or other services from the Bergen University of Norway for research writing; and other financial or nonfinancial interests from Dean Public Health and Preventive Medicine King Edward Medical University; outside the submitted work. M.S. Aslam reports two grants from Xiamen University Malaysia Research Fund (XMUMRF). Grant no.: XMUMRF/2025-C15/ITCM/0006. Project title: Therapeutic and Toxicity Evaluation of Selected Medicinal Herbs for NAFLD: Exploring the Inter-Organelle Contact Sites Modulation. Theory Role: Co-Investigator Dates: January 2025–December 2027 (ongoing). Internal XMUMRF research grant administered by Xiamen University Malaysia, funds disbursed to institutional research accounts only; no salary, honoraria or personal payments to author. Grant no.: XMUMRF/2023-C11/ISEM/0041. Project title: Children’s Rights Education in the Early Years of Divorce: An Exploration of Adolescents’ Perspectives. Role: Co-Investigator Dates: January 2023–December 2025 (ongoing). Internal XMUMRF research grant administered by Xiamen University Malaysia; funds disbursed to institutional research account only; no salary, honoraria or personal payments to author; all outside the submitted work. A.S.B. reports support for attending meetings and/or travel to the American Public Health Conference 2022, 2023 and 2024; American College of Epidemiology 2023, 2024 and 2025; Military Health System Conference 2024; and from the University of Virginia Biomedical Data Science Innovation Lab and Seminar series; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, as a member of the Board of Directors of the American College of Epidemiology 2024–present; former co-chair of the Publications Committee of the American College of Epidemiology in 2023 and 2024; liaison for the Publications Committee of the American College of Epidemiology in 2024 and 2025; Communications Chair for the American Public Health Association, Health Informatics and Information Technology Section; Associate Editor, Annals of Epidemiology Journal; all outside of the submitted work. S.B. reports grants or contracts from the Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), Grant-in-Aid for Scientific Research (KAKENHI; Grant ID 23KF0126), JSPS and the Australian Academy of Science, JSPS International Fellowship (Grant ID P23712); leadership or fiduciary roles in other board, society, committee or advocacy groups, paid or unpaid, as District Chair, Diversity, Equity, Inclusion & Belonging of Rotary District 9675 (Sydney, Australia), as Chair, Founding Member and Manager of the Global Health & Migration Hub Community, Global Health Hub Germany (Berlin, Germany), as Editorial Board Member of PLOS One, BMC Neurology, Frontiers in Neurology, Frontiers in Stroke, Frontiers in Public Health, Journal of Aging Research, Neurology International, Diagnostics and BMC Medical Research Methodology; as a member of the College of Reviewers, Canadian Institutes of Health Research (CIHR), Government of Canada; as the Director of Research of World Headache Society (Bengaluru, India); as Expert Adviser/Reviewer of Cariplo Foundation (Milan, Italy); as Visiting Director of National Cerebral and Cardiovascular Center, Department of Neurology, Division of Cerebrovascular Medicine and Neurology, Suita (Osaka, Japan); as Member, Scientific Review Committee of Cardiff University Biobank (Cardiff, UK); as Chair of Rotary Reconciliation Action Plan; and Healthcare and Medical Adviser at Japan Connect (Osaka, Japan); outside the submitted work. A. Caye reports consulting fees from EMS, Knight Therapeutics; outside the submitted work. S.R.C. reports grants or contracts from Janssen Cilag Australia Investigator Initiated Research Grants; Australian NHMRC, MMRF Research Grants; NIMH Research Grants; and XWPharma contract research; all funds paid to the University of Adelaide; consulting fees from Insight Timer and Preventative Health SA; all funds paid to the University of Adelaide; and payment or honoraria for lectures, presentations, speakers bureaus, manuscripts writing or educational events from Servier, Lundbeck-Otsuka, all funds paid to the University of Adelaide; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid, with the Board of Mental Health Foundation of Australia; outside the submitted work. X.D. reports all support for the present manuscript from the Institute for Health Metrics and Evaluation and University of Washington. E.E. reports grants or contracts from Grand Challenges Canada, Canadian Institutes of Health Research, funds paid to their institution; and leadership or fiduciary role in other board, society, committee or advocacy group, unpaid, with Global Implementation Society; outside the submitted work. I.F.E.B. reports leadership or fiduciary role in other board, society, committee or advocacy group as Editor in Chief of Recent Advances in Infectious Diseases and as an Editor for Texila American Journals; outside the submitted work. O.F.F. reports leadership or fiduciary role in other board, society, committee or advocacy group, unpaid, with the African Tobacco Control Alliance; outside the submitted work. A. Faro reports support for the present manuscript from the National Council for Scientific and Technological Development (CNPq, Brazil). J.F. reports grants or contracts from the National Institute of Mental Health and the National Institute on Drug Abuse; outside the submitted work. J.J.J. reports payment for honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Adamed, Amgen, Boehringer Ingelheim and Sevier; outside the submitted work. S.V.K. reports grants or contracts from the National Institute for Health & Care Research, funds paid to their institution; outside the submitted work. M. Koscik reports grants or contracts from NPO ‘Systemic Risk Institute’ number LX22NPO5101, funded by the European Union – Next Generation EU (Ministry of Education, Youth, and Sports); outside the submitted work. P. Meylakhs reports grants or contracts from the Center for Comparative Research of Social Wellbeing, HSE University; outside the submitted work. T.R.M. reports grants or contracts from the National Institute of Mental Health, payments made to their employer; payment for expert testimony for opioid litigations, payments made to their employer; and from Opioid litigation, Evre, LLC, payments made to them; outside the submitted work. L. Monasta reports support for the present manuscript from the Italian Ministry of Health, payments made to their institution. R.F.P.-A. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Angelini, Casen Recordati, Lundbeck, Neuraxpharm, Rubió, Servier and Takeda; support for attending meetings and/or travel from Angelini, Italfarmaco, Advanz Pharma, Takeda, Lundbeck and Camurus; all outside the submitted work. S.K.P. reports support for the present manuscript from Siksha ‘O’ Anusandhan (Deemed to be University); grants and contracts from File no. 17-59/2023-24/CCRH/Tech./Coll./ICMR-Diabetes/960; outside the submitted work. G.D.P. reports support for attending meetings and/or travel from Roche Hellas and Bayer Greece; outside the submitted work. R. Passera reports participation on a Data Safety Monitoring Board or Advisory Board with the Data Safety Monitoring Board dello studio ‘Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKitreated/ineligible Relapse/Refractory Mantle Cell Lymphoma (MCL) patients’ – FIL, Fondazione Italiana Linfomi, Alessandria (Italy); leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with EBMT Statistical Committee, European Society for Blood and Marrow Transplantation, Paris, France; and is a former member from 2020 to 2023 of the IRB/IEC Comitato Etico AO SS. Antonio e Biagio Alessandria-ASL AL-VC (Italy); outside the submitted work. A.E.P. reports support for the present manuscript from the Australian National Health and Medical Research Council (Grant no. APP2009306). V. Sharma acknowledges support from DFSS (MHA)’s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India, and RUSA grant to Panjab University by Ministry of Education, Govt. of India; outside the submitted work. J.I.S. reports support from the Yonsei Foundation, funded by Lee Youn Jae. J.P.S. reports support for the present manuscript from the Portuguese Foundation for Science and Technology. L.M.L.R.S. reports grants or contracts with SPRINT – Sport Physical Activity and Health Research e Innovation Center, Polytechnic of Guarda, 6300-559 6 Guarda, Portugal; and collaboration with RISE–UBI, Health Sciences Research Centre, University of Beira Interior, 6201-506 Covilhã, Portugal; outside the submitted work. J.A.S. reports consulting fees from ROMTech, Atheneum, Clearview Healthcare Partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals, DINORA, ANI/Exeltis, USA Inc., Frictionless Solutions, Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care Options, Putnam Associates, FocusForward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, Practice Point Communications and the National Institutes of Health; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Simply Speaking; support for attending meetings and/or travel from OMERACT, an international organization that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies, as past steering committee member to attend their meeting every 2 years; participation on a Data Safety Monitoring Board or Advisory Board with FDA Arthritis Advisory Committee (unpaid); leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, as a past steering committee member of the OMERACT; stock or stock options in Atai Life Sciences, Kintara Therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., Aebona Pharmaceuticals and Charlotte’s Web Holdings, Inc., and previously owned stock options in Amarin, Viking and Moderna Pharmaceuticals; all outside the submitted work. D.J.S. reports consultancy honoraria from Discovery Vitality, Kanna, L’Oreal, Lundbeck, Orion, Servier, Seaport Therapeutics, Takeda and Wellcome. R.T.-S. reports grants or contracts from Valencian Regional Government’s Ministry of Education (PROMETEO/CIPROM/2022/58) and the Spanish Ministry of Science, Innovation and Universities (PID2021-129099OB-I00). The funders were not involved in the design of the manuscript or decision to submit the manuscript for publication, nor will they be involved in any aspect of the study’s conduct; all outside the submitted work. S.J.T. reports grants or contracts from part of the 2023/4 Adult Psychiatric Morbidity Survey team, collecting epidemiological data on community-based adults living in England. This is a contracted study from NHS Digital, via the Department of Health and Social Care. S.J.T. has also contributed to multiple chapters of the 2023/4 Adult Psychiatric Morbidity Survey report, payments made to the University of Leicester. S.J.T. led a study funded by the National Institute for Health and Care Research Clinical Research Network, on optimizing survey design for people with learning disability and autistic people, payments made to the University of Leicester. S.J.T. led a study from the National Institute for Health and Care Research related to reviewing a national training program for health and social care professionals relating to learning disability and autism, payments made to the University of Leicester. S.J.T. was co-applicant on a study funded by the National Institute for Health and Care Research related to identification, recording and reasonable adjustments for people with a learning disability and autistic people in NHS electronic clinical record systems, payments made to the University of Leicester. S.J.T. was co-applicant on a study funded by the National Institute for Health and Care Research related to medication support interventions and strategies for people with learning disabilities, payments made to the University of Leicester. S.J.T. was lead applicant on a study funded by the Baily Thomas Charitable Fund investigating barriers, enablers and interventions to facilitate deprescribing for people with intellectual disability, payments made to the University of Leicester. S.J.T. reports support for attending meetings and/or travel from the Royal College of Psychiatrists for accommodation and travel to conference events due to their role as academic secretary in the faculty of the Psychiatry of Intellectual Disability, as well as additional conference fees waived for Royal College of Psychiatrists; leadership or fiduciary roles as Academic Secretary for the Neurodevelopmental Psychiatry Special Interest Group and Psychiatry of Intellectual Disability Faculty at the Royal College of Psychiatrists; Associate Editor for Journal of Mental Health Research in Intellectual Disabilities; Editorial Board Member for Progress in Neurology and Psychiatry, Advances in Mental Health and Intellectual Disability, Advances in Autism, BMC Psychiatry and BJPsych Open (no payments received for these roles); royalties received as Editor of Psychiatry of Intellectual Disability Across Cultures (Oxford University Press); outside the submitted work. A.C.T. reports support for the present manuscript from the US National Institutes of Health (K34DA061696); leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, from Elsevier, Inc. as Co-editor in Chief of SSM – Mental Health, and from BMJ Publishing Group, Ltd, as Clinical Editorial Advisor for The BMJ; outside the submitted work. M.Z. is an Alexion, AstraZeneca Rare Disease employee.

Peer review

Peer review information

Nature Medicine thanks Johannes Thrul and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Ming Yang, in collaboration with the Nature Medicine team.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 World map of age-standardized prevalence and DALYs rates per 100,000 population attributable to overall drug use disorders for both sexes across 204 countries, 2023.

Abbreviations: DALYs, disability-adjusted life year; DUD, drug use disorders. The color gradient, ranging from purple (low value) to red (high value), indicates the magnitude of each estimate. Data from the Institute for Health Metrics and Evaluation.

Extended Data Fig. 2 Age-standardized DALYs per 100,000 population attributable to drug use disorders for both sexes across the top 30 countries, 2023.

(A) Total burden of DALYs for drug use disorders; (B) DALYs rate for each drug use disorder. Abbreviations: AUD, amphetamine use disorders; CAUD, cannabis use disorders; CUD, cocaine use disorders; DALYs, disability-adjusted life year; OUD, opioid use disorders.

Extended Data Fig. 3 Regional trends in prevalence and DALYs per 100,000 population for drug use disorders by GBD regions, 1990-2023.

(A) Total burden of DALYs rate for drug use disorders; (B) DALYs rate for each drug use disorder. Abbreviations: AUD, amphetamine use disorders; CAUD, cannabis use disorders; CUD, cocaine use disorders; DALYs, disability-adjusted life year; OUD, opioid use disorders.

Extended Data Fig. 4 Percentage change in age-standardized DALYs per 100,000 population for drug use disorders by GBD regions, 2023.

Abbreviations: AUD, amphetamine use disorders; CAUD, cannabis use disorders; CUD, cocaine use disorders; DALYs, disability-adjusted life year; OUD, opioid use disorders.

Extended Data Fig. 5 DALY per 100,000 population of drug use disorders for both sexes by SDI and age group, 2023.

Countries were categorized into five SDI groups according to the GBD SDI classification, low (32 countries), low-middle (41 countries), middle (40 countries), high-middle (47 countries), and high (44 countries). Abbreviations: AUD, amphetamine use disorders; CAUD, cannabis use disorders; CUD, cocaine use disorders; DALYs, disability-adjusted life year; OUD, opioid use disorders; SDI, socio demographic index.

Extended Data Fig. 6 Changes in the number of DALYs cases (millions) associated with aging, epidemiological change, and population by each drug use disorders, 1990-2023.

Abbreviations: AUD, amphetamine use disorders; CAUD, cannabis use disorders; CUD, cocaine use disorders; DALYs, disability-adjusted life year; OUD, opioid use disorders.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kang, J., Kim, H.J., Kim, M.S. et al. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study.
Nat Med (2026). https://doi.org/10.1038/s41591-025-04137-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41591-025-04137-0